Re: [爆卦] 賽諾菲和葛蘭素失敗的疫苗1/2期實驗

: 六月解盲，陳時中部長只說看抗體反應 (從一期結果猜測抗體過關的機會不低)
: 猜測沒提預防效果是因為不容易達到統計上顯著差異(受試者少且盛行率低)
: 如果抗體及預防感染都顯著，解盲成功當然成功
: 如果預防感染未達顯著，抗體顯著，專家會議會如何判定呢？

May 19, 2021 摘錄自PTT Stock板 作者 zzahoward

(FDA這篇是在說抗體檢測不能判斷免疫能力或本身對病毒的抗性)

原文標題：

FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to
Evaluate Immunity or Protection From COVID-19, Including After Vaccination

原文連結：

https://tinyurl.com/34znv66p

原文內容：

“The FDA is reminding the public of the limitations of COVID-19 antibody, or
serology, testing and providing additional recommendations about the use of
antibody tests in people who received a COVID-19 vaccination.

Antibody tests can play an important role in identifying individuals who may
have been exposed to the SARS-CoV-2 virus and may have developed an adaptive
immune response. However, antibody tests should not be used at this time to
determine immunity or protection against COVID-19 at any time, and especiallyafter a person has received a COVID-19 vaccination.

The FDA will continue to monitor the use of authorized SARS-CoV-2 antibody
tests for purposes other than identifying people with an adaptive immune
response to SARS-CoV-2 from a recent or prior infection.”

大致翻譯如下

FDA認為可以用SARS-CoV-2抗體來進行辨識接觸病毒歷史

但FDA表示抗體並不能代表免疫力或保護力(減少重症)

"尤其是使用過COVID-19之疫苗後"

國產疫苗二期只有中和抗體效價的數據 (補充，中和抗體和總抗體是不同的東西)

也就是說，依照此數據推估出來的效力或是保護力，都無法經過檢驗或承認

--
收錄一下結論

一個沒有效力數據的疫苗要怎麼進行戰略調度呢?

以上用FDA的最新資料回答一下

--
佛劍語錄：徘徊世間的無主幽魂 掙扎在生死之間 是怎樣的的苦處
吾非自地獄而回 而是生在無間之中
捨身如來 無間輪迴 佛劍之路 不由分說
小活佛：聖行者相信天命嗎? 佛劍分說：相信

--

※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 117.56.185.21 (臺灣)